Over the past 10 years, MetLife (MET) earnings per share (EPS) grew 3.3% a year, revenue grew 2.3% a year and free cash flow grew 3.1% a year, with an average return on invested capital (ROIC) of 803.5%. MET stock trades at $100.33, a P/E of 10.3, below its historical average of 16.2. Analysts' average 12-month price target is $108.25 (+7.9%).
MetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.S.
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | -3.4% | -12.2% | 2.0% | F |
| EPS GrowthEPS | 3.3% | -3.4% | 24.0% | C+ |
| Revenue GrowthRevenue | 2.3% | 2.6% | 9.0% | C |
| Cash Flow GrowthCash Flow | 3.1% | 9.5% | 5.2% | C+ |
| ROICROIC | 803.5% | 1.0% | 0.7% | A- |
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $60.22 | $61.64 | $56.23 | $52.02 | $70.04 | $81.64 | $77.62 | $36.94 | $39.37 | $38.60 | $42.71 | $41.85 | |
| Basic EPSEPS | $3.48 | $0.68 | $3.74 | $4.95 | $6.10 | $5.72 | $7.70 | $6.35 | $1.82 | $5.98 | $4.80 | $9.77 | |
| RevenueRevenue | $61,343,000,000 | $60,527,000,000 | $62,308,000,000 | $67,941,000,000 | $69,620,000,000 | $67,887,000,000 | $63,366,000,000 | $67,965,000,000 | $67,709,000,000 | $69,939,000,000 | $77,084,000,000 | $78,646,000,000 | |
| Free Cash FlowCash Flow | $13,345,000,000 | $14,663,000,000 | $12,719,000,000 | $9,526,000,000 | $13,925,000,000 | $11,508,000,000 | $12,827,000,000 | $11,373,000,000 | $14,260,000,000 | $15,116,000,000 | $18,105,000,000 | $16,571,000,000 | |
| ROIC (%)ROIC | 4061.0% | 1482.6% | 741.3% | 1913.4% | 2514.5% | 1378.6% | 1.4% | 1.3% | 0.4% | 1.1% | 0.7% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
33 firms rate it — 26 buy, 7 hold · Most recent Oct 2026
The average 12-month analyst price target for MET is $108.25, with a range of $103.00 to $111.00. That is +7.9% from the current price of $100.33.
Most rate it a buy. Of 33 firms covering MetLife, the ratings are 26 buy or strong buy, 7 hold and 0 sell or strong sell.
Annual growth rates for MET. EPS: 3.3% over 10 years, -3.4% over 5 years, 24.0% over 1 year. Revenue: 2.3% over 10 years, 2.6% over 5 years, 9.0% over 1 year. Free cash flow: 3.1% over 10 years, 9.5% over 5 years, 5.2% over 1 year. Book value per share: -3.4% over 10 years, -12.2% over 5 years, 2.0% over 1 year.
MetLife's return on invested capital (ROIC) was 0.7% in fiscal 2025. Its 10-year average ROIC is 803.5%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
MET's current P/E ratio is 10.3, compared with a historical average of 16.2. Trailing earnings per share are $9.77.
MET last traded at $100.33 as of October 19, 2026. Its 52-week range is $67.33 to $102.43. MetLife has a market cap of $63.76B.
Data as of October 19, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.